NCT02642042 2026-03-04
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
National Cancer Institute (NCI)
Erasca, Inc.
Novartis
M.D. Anderson Cancer Center
Deciphera Pharmaceuticals, LLC